165 related articles for article (PubMed ID: 32567515)
1. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma.
Mariuk-Jarema A; Koseła-Paterczyk H; Rogala P; Klimczak A; Wągrodzki M; Maksymiuk B; Rutkowski P
Tumori; 2020 Dec; 106(6):NP9-NP13. PubMed ID: 32567515
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic options for alveolar soft part sarcoma: antiangiogenic therapy, immunotherapy and beyond.
Brahmi M; Vanacker H; Dufresne A
Curr Opin Oncol; 2020 Jul; 32(4):295-300. PubMed ID: 32541316
[TBL] [Abstract][Full Text] [Related]
3. Treatment of a case of primary alveolar soft part sarcoma of the lung: Case report and literature review.
Li F; Lu H; Zhao D; Shen Z
J Int Med Res; 2023 Jun; 51(6):3000605231174973. PubMed ID: 37282499
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of advanced alveolar soft part sarcoma with sunitinib: A case report.
Ye C; Wang J; Li W; Yuan M; Chai Y
Medicine (Baltimore); 2018 Dec; 97(51):e13584. PubMed ID: 30572461
[TBL] [Abstract][Full Text] [Related]
5. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.
Su H; Yu C; Ma X; Song Q
Invest New Drugs; 2021 Oct; 39(5):1411-1418. PubMed ID: 33765213
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review.
Paoluzzi L; Maki RG
JAMA Oncol; 2019 Feb; 5(2):254-260. PubMed ID: 30347044
[TBL] [Abstract][Full Text] [Related]
7. Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group.
Malouf GG; Beinse G; Adam J; Mir O; Chamseddine AN; Terrier P; Honore C; Spano JP; Italiano A; Kurtz JE; Coindre JM; Blay JY; Le Cesne A
Oncologist; 2019 Jul; 24(7):980-988. PubMed ID: 30626710
[TBL] [Abstract][Full Text] [Related]
8. [Two cases with metastatic intracerebral alveolar soft part sarcoma].
Kageji T; Kannuki S; Hondo H; Matsumoto K; Nakamura M; Yamashita S
No Shinkei Geka; 1995 Jul; 23(7):627-32. PubMed ID: 7637847
[TBL] [Abstract][Full Text] [Related]
9. Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.
Lewin J; Davidson S; Anderson ND; Lau BY; Kelly J; Tabori U; Salah S; Butler MO; Aung KL; Shlien A; Dickson BC; Abdul Razak AR
Cancer Immunol Res; 2018 Sep; 6(9):1001-1007. PubMed ID: 30018044
[TBL] [Abstract][Full Text] [Related]
10. Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma.
Yang Y; Beeraka NM; Liu J; Zuo X; Wang X; Li T; Fan R
Curr Pharm Des; 2022; 28(41):3404-3412. PubMed ID: 36154597
[TBL] [Abstract][Full Text] [Related]
11. iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study.
Mcaddy NC; Saffar H; Litière S; Jespers P; Schöffski P; Messiou C
Cancer Imaging; 2020 Oct; 20(1):79. PubMed ID: 33121537
[TBL] [Abstract][Full Text] [Related]
12. Molecular Landscape in Alveolar Soft Part Sarcoma: Implications for Molecular Targeted Therapy.
Soheilifar MH; Taheri RA; Zolfaghari Emameh R; Moshtaghian A; Kooshki H; Motie MR
Biomed Pharmacother; 2018 Jul; 103():889-896. PubMed ID: 29710505
[TBL] [Abstract][Full Text] [Related]
13. Complete Response to Dual Immunotherapy in a Young Adult with Metastatic Alveolar Soft Part Sarcoma Enabled by a Drug Recovery Program in a Community Practice.
Conry A; Peters M; Fried DB; Adams A; Campbell AW; Bearden JD; Siegel RD; Crosswell HE
J Adolesc Young Adult Oncol; 2020 Jun; 9(3):449-452. PubMed ID: 31855495
[TBL] [Abstract][Full Text] [Related]
14. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
Shi Y; Cai Q; Jiang Y; Huang G; Bi M; Wang B; Zhou Y; Wang G; Ying H; Tao Z; Shi C; Guo Q; Gao C
Clin Cancer Res; 2020 Dec; 26(24):6445-6452. PubMed ID: 33046518
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
Bergsma EJ; Elgawly M; Mancuso D; Orr R; Vuskovich T; Seligson ND
Ann Pharmacother; 2024 Apr; 58(4):407-415. PubMed ID: 37466080
[TBL] [Abstract][Full Text] [Related]
16. Metastatic alveolar soft part sarcoma presenting as a dural-based cerebral mass.
Perry JR; Bilbao JM
Neurosurgery; 1994 Jan; 34(1):168-70. PubMed ID: 8121554
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 "CREATE" Trial.
Lee CJ; Modave E; Boeckx B; Kasper B; Aamdal S; Leahy MG; Rutkowski P; Bauer S; Debiec-Rychter M; Sciot R; Lambrechts D; Wozniak A; Schöffski P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628499
[TBL] [Abstract][Full Text] [Related]
18. Lingual alveolar soft part sarcoma responsive to pazopanib: A case report.
Yoshihiro T; Tsuchihashi K; Nio K; Arita S; Nakano T; Yasumatsu R; Jiroumaru R; Ariyama H; Kusaba H; Oda Y; Akashi K; Baba E
Medicine (Baltimore); 2017 Nov; 96(44):e8470. PubMed ID: 29095301
[TBL] [Abstract][Full Text] [Related]
19. Alveolar soft part sarcoma metastatic to the breast: a case report.
Asano Y; Kashiwagi S; Takada K; Tokimasa S; Takashima T; Ohsawa M; Hirakawa K; Ohira M
BMC Surg; 2019 Mar; 19(1):30. PubMed ID: 30832622
[TBL] [Abstract][Full Text] [Related]
20. Alveolar soft part sarcoma metastatic to the mandible: A report and review of literature.
Peters SM; Perrino MA; Yoon AJ; Philipone EM
J Stomatol Oral Maxillofac Surg; 2017 Dec; 118(6):379-382. PubMed ID: 28774857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
